SBRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sabra Health Care REIT Inc (SBRA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive signals such as bullish technical indicators and a favorable sector outlook, the company's recent financial performance shows significant declines in net income and EPS, and analysts remain mostly neutral on the stock. The lack of strong trading trends, recent news, or significant catalysts further supports a hold recommendation.
The technical indicators show a bullish trend with the MACD histogram at 0.148 (positively expanding), RSI at 84.497 (indicating overbought conditions), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 19.968, R2: 20.549) in pre-market at $20.01, suggesting limited immediate upside potential.
Analysts have raised price targets recently (e.g., Jefferies to $22 and Wells Fargo to $21).
The healthcare REIT sector is viewed favorably due to demographic tailwinds and a strong supply/demand backdrop.
SwingMax sent an entry signal on 2026-02-05, with a 4.00% price increase since then.
Financial performance in Q4 2025 showed a significant decline in net income (-41.70% YoY) and EPS (-42.11% YoY).
Gross margin dropped to 0, indicating operational challenges.
The stock has a 50% chance of declining in the next week (-3.78%) and month (-4.83%).
Analysts remain neutral overall, with some expressing concerns about occupancy and cash NOI margins.
In Q4 2025, revenue increased by 16.21% YoY to $211.9M, but net income dropped by 41.70% YoY to $27.2M, and EPS fell by 42.11% YoY to $0.11. Gross margin dropped to 0, reflecting operational inefficiencies.
Analysts have mixed views: Jefferies maintains a Buy rating with a $22 price target, while Truist and UBS remain Neutral with price targets of $21 and $20, respectively. Analysts highlight improving fundamentals in the healthcare REIT sector but note that the stock is not particularly cheap and faces challenges in occupancy and NOI margins.
